Jeff Reese
Last active: 1/7/2021

Outcomes in infants < 29 weeks of gestation following single-dose prophylactic indomethacin.

Gillam-Krakauer M, Slaughter JC, Cotton RB, Robinson BE, Reese J, Maitre NL
J Perinatol. 2020

PMID: 32948814 · PMCID: PMC7499931 · DOI:10.1038/s41372-020-00814-9

BACKGROUND - Prophylactic indomethacin (3 doses) decreases patent ductus arteriosus (PDA) and intraventricular hemorrhage (IVH) in preterm infants. The study aim was to determine whether single-dose indomethacin (SD-INDO) decreases PDA, IVH, and improves motor function.

METHODS - A retrospective cohort (2007-2014) compared infants born < 29 weeks who did (n = 299) or did not (n = 85) receive SD-INDO and estimated outcomes association with ordinal logistic regression, adjusting for multiple variables using propensity scores.

RESULTS - Infants who received SD-INDO were more premature (p < 0.001) but had lower odds of PDA (OR 0.26 [0.15, 0.44], p < 0.005), PDA receiving treatment (OR 0.12 [0.03, 0.47], p < 0.005), death (OR 0.41 [0.20, 0.86], p = 0.02), and CP severity (OR 0.33 [0.12, 0.89], p = 0.03). There was less IVH (OR 0.58 [0.36, 0.94], p = 0.03) when adjusted for gestational age.

CONCLUSIONS - SD-INDO is associated with decreased PDA and CP severity and improved survival.

MeSH Terms (0)

Connections (1)

This publication is referenced by other Labnodes entities:

Links